Stock comparison
Haemonetics
Neurocrine Biosciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
NBIX
Neurocrine Biosciences
Market cap
$15.76B
Sector
Healthcare
Overall winner
Neurocrine Biosciences NBIX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | NBIX | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 68B | HAE |
| Benjamin Graham | 85A | 78B | HAE |
| Philip Fisher | 60C | 80A | NBIX |
| Peter Lynch | 54C | 65B | NBIX |
| Joel Greenblatt | 31F | 55C | NBIX |
| Charlie Munger | 54D | 60C | NBIX |
| Terry Smith | 55D | 63D | NBIX |
Side-by-side metrics
| Metric | HAE | NBIX |
|---|---|---|
| Market cap | $2.98B | $15.76B |
| P/E (TTM) | 24.8x | 22.6x |
| EV/EBIT | 14.1x | 24.7x |
| ROIC (TTM) | 8.37% | 13.68% |
| Gross margin | 55.74% | 98.17% |
| Net margin | 7.29% | 21.55% |
| Revenue CAGR 5y | 7.65% | 26.04% |
| EPS CAGR 5y | 24.62% | 50.0% |
| Debt / Equity | 1.5x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 24.7x+43%
NBIX leads on
- Debt / Equity0.1xvs 1.5x+92%
- Market cap$15.76Bvs $2.98B+81%
- Revenue CAGR 5y26.04%vs 7.65%+71%
- Net margin21.55%vs 7.29%+66%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.